Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility are currrently unavailable.

Bakhos A. Tannous, Ph.D.

Co-Author

This page shows the publications co-authored by Bakhos Tannous and Christian Badr.
Connection Strength

7.200
  1. Obtusaquinone: A Cysteine-Modifying Compound That Targets Keap1 for Degradation. ACS Chem Biol. 2020 06 19; 15(6):1445-1454.
    View in: PubMed
    Score: 0.896
  2. An allosteric inhibitor of SHP2 effectively targets PDGFRa-driven glioblastoma. Neuro Oncol. 2019 11 04; 21(11):1348-1349.
    View in: PubMed
    Score: 0.865
  3. A TNF-NF-?B-STAT3 loop triggers resistance of glioma-stem-like cells to Smac mimetics while sensitizing to EZH2 inhibitors. Cell Death Dis. 2019 03 19; 10(4):268.
    View in: PubMed
    Score: 0.828
  4. Targeting cancer cells with the natural compound obtusaquinone. J Natl Cancer Inst. 2013 May 01; 105(9):643-53.
    View in: PubMed
    Score: 0.546
  5. Bioluminescence imaging: progress and applications. Trends Biotechnol. 2011 Dec; 29(12):624-33.
    View in: PubMed
    Score: 0.487
  6. Lanatoside C sensitizes glioblastoma cells to tumor necrosis factor-related apoptosis-inducing ligand and induces an alternative cell death pathway. Neuro Oncol. 2011 Nov; 13(11):1213-24.
    View in: PubMed
    Score: 0.486
  7. Functional drug screening assay reveals potential glioma therapeutics. Assay Drug Dev Technol. 2011 Jun; 9(3):281-9.
    View in: PubMed
    Score: 0.468
  8. Suicidal gene therapy in an NF-?B-controlled tumor environment as monitored by a secreted blood reporter. Gene Ther. 2011 May; 18(5):445-51.
    View in: PubMed
    Score: 0.467
  9. Real-time monitoring of nuclear factor kappaB activity in cultured cells and in animal models. Mol Imaging. 2009 Sep-Oct; 8(5):278-90.
    View in: PubMed
    Score: 0.427
  10. A highly sensitive assay for monitoring the secretory pathway and ER stress. PLoS One. 2007 Jun 27; 2(6):e571.
    View in: PubMed
    Score: 0.367
  11. Erratum: Author Correction: Sustained NF-?B-STAT3 signaling promotes resistance to Smac mimetics in Glioma stem-like cells but creates a vulnerability to EZH2 inhibition. Cell Death Discov. 2019; 5:103.
    View in: PubMed
    Score: 0.211
  12. Sustained NF-?B-STAT3 signaling promotes resistance to Smac mimetics in Glioma stem-like cells but creates a vulnerability to EZH2 inhibition. Cell Death Discov. 2019; 5:72.
    View in: PubMed
    Score: 0.206
  13. Dissecting inherent intratumor heterogeneity in patient-derived glioblastoma culture models. Neuro Oncol. 2017 06 01; 19(6):820-832.
    View in: PubMed
    Score: 0.183
  14. Systemically administered AAV9-sTRAIL combats invasive glioblastoma in a patient-derived orthotopic xenograft model. Mol Ther Oncolytics. 2016; 3:16017.
    View in: PubMed
    Score: 0.171
  15. Intracranial AAV-sTRAIL combined with lanatoside C prolongs survival in an orthotopic xenograft mouse model of invasive glioblastoma. Mol Oncol. 2016 Apr; 10(4):625-34.
    View in: PubMed
    Score: 0.165
  16. Systemic anticancer neural stem cells in combination with a cardiac glycoside for glioblastoma therapy. Stem Cells. 2014 Aug; 32(8):2021-32.
    View in: PubMed
    Score: 0.150
  17. Triple bioluminescence imaging for in vivo monitoring of cellular processes. Mol Ther Nucleic Acids. 2013 Jun 18; 2:e99.
    View in: PubMed
    Score: 0.139
  18. A secreted luciferase for ex vivo monitoring of in vivo processes. Nat Methods. 2008 Feb; 5(2):171-3.
    View in: PubMed
    Score: 0.096
  19. Visualization and tracking of tumour extracellular vesicle delivery and RNA translation using multiplexed reporters. Nat Commun. 2015 May 13; 6:7029.
    View in: PubMed
    Score: 0.040
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.